China’s top pricing regulator on Wednesday announced its decision to penalize US Medtronic for price fixing, the first penalty on a medical device maker handed down by the central authority.
Medtronic was fined for $17.27 million, 4 percent of the company’s annual sales in 2015, due to violating the anti-monopoly law and eliminating market competition of medical device manufacturing industry, according to the National Development and Reform Commission.
The investigation discovered that since at least 2014 the company had fixed the resale price through monopoly agreements with it trading counterparts, namely its distributors.
Competition among distributors plays a key role in ensuring the formation of a reasonable market price at the time when high-end implantable medical equipment market competition is not sufficient in China, according to the commission.
Full Content: China Daily
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Hong Kong Authorities Crack Down on Bid-Rigging: 20 Arrested in Corruption Sweep
Apr 18, 2024 by
CPI
EU’s Vestager Cautions Against Telecoms Merger Threats to Competition
Apr 18, 2024 by
CPI
EU Regulators Set to Clear Microsoft’s $13B OpenAI Investment
Apr 17, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – China Edition – Year of the Dragon
Apr 16, 2024 by
CPI
Review Logic and Rules for Concentrations of Undertakings that Do Not Meet the Standard of Notification
Apr 16, 2024 by
CPI
China’s Review of Semiconductor Transactions
Apr 16, 2024 by
CPI
Key Challenges and Tips for Merger Control Filing in China for Listed Companies
Apr 16, 2024 by
CPI
Key Point Review: China SPC Antitrust Judgments in 2023
Apr 16, 2024 by
CPI